Tislelizumab in advanced/metastatic esophageal squamous cell carcinoma: health related quality of life in Asian patients

CONCLUSIONS: Overall, the health-related quality of life and ESCC-related symptoms of patients receiving tislelizumab in the Asian subgroup remained stable or improved, while patients receiving investigator-chosen chemotherapy experienced worsening. These results in Asian patients corroborate the findings in the intent-to-treat population suggesting tislelizumab is a potential new second-line treatment option for patients with advanced or metastatic ESCC.TRIAL REGISTRATION: The RATIONALE-302 study is registered on clinicaltrials.gov as NCT03430843.PMID:37846080 | DOI:10.1080/03007995.2023.2270894

Source: Current Medical Research and Opinion - October 17, 2023 Category: Research Authors: Sung-Bae Kim Eric Van Cutsem Jaffer Ajani Lin Shen Gisoo Barnes Ningning Ding Aiyang Tao Tianyu Xia Lin Zhan Ken Kato Source Type: research